Please login to the form below
Olumiant
This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.
Cambridge University scientists identify 160 new drugs with COVID-19 repurposing potential
In April, the European Medicines Agency (EMA) launched a rolling review of one of these repurposed drugs – Eli Lilly’s rheumatoid arthritis/eczema treatment Olumiant (baricitinib) – as a treatment of
Latest news
-
EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
Among the five therapeutic candidates identified are Eli Lilly’s repurposed arthritis medicine Olumiant (baricitinib) and investigational antibody drugs for early-stage COVID-19. ... The European Medicines Agency (EMA) is currently assessing an
-
Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales
This increase can be attributed to Lily’s key growth products, including Trulicity, Verzenio, Olumiant, Tyvyt, Emgality, Jardiance, Retevmo, Cyramza and Taltz.
-
Researchers use AI to identify drugs that could be repurposed for Alzheimer’s
Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing. ... One of the drugs identified using the DRIAD method was Eli Lilly’s Olumiant(baricitinib), which will be investigated in a clinical trial for patients with
-
Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval
35%. Baricitinib is already marketed by Lilly as Olumiant, for the treatment of adults with moderate to severe rheumatoid arthritis in the US.
-
Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures
inhibitor Olumiant (baricitinib) for the novel coronavirus.
More from news
Approximately 7 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
NICE – but not enough
Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year. ... Today – more than three years after its NICE TA – Olumiant is finally approaching full implementation.
-
Drug launches to watch in 2019
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen’s Aduhelm unlikely to get approval in Europe
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- The pandemic preparedness paradox
- First trial of a vaccine against Alzheimer’s launches
- Good NICE news for Pfizer, but Dendreon drug rejected
PMHub
11 London
The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
